BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 16722663)

  • 1. Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites.
    Gemma S; Gabellieri E; Huleatt P; Fattorusso C; Borriello M; Catalanotti B; Butini S; De Angelis M; Novellino E; Nacci V; Belinskaya T; Saxena A; Campiani G
    J Med Chem; 2006 Jun; 49(11):3421-5. PubMed ID: 16722663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
    Camps P; El Achab R; Görbig DM; Morral J; Muñoz-Torrero D; Badia A; Eladi Baños J; Vivas NM; Barril X; Orozco M; Luque FJ
    J Med Chem; 1999 Aug; 42(17):3227-42. PubMed ID: 10464010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors.
    Savini L; Gaeta A; Fattorusso C; Catalanotti B; Campiani G; Chiasserini L; Pellerano C; Novellino E; McKissic D; Saxena A
    J Med Chem; 2003 Jan; 46(1):1-4. PubMed ID: 12502352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
    Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Scarpellini M; Viayna E; Badia A; Clos MV; Camins A; Pallàs M; Bartolini M; Mancini F; Andrisano V; Estelrich J; Lizondo M; Bidon-Chanal A; Luque FJ
    J Med Chem; 2008 Jun; 51(12):3588-98. PubMed ID: 18517184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.
    Butini S; Campiani G; Borriello M; Gemma S; Panico A; Persico M; Catalanotti B; Ros S; Brindisi M; Agnusdei M; Fiorini I; Nacci V; Novellino E; Belinskaya T; Saxena A; Fattorusso C
    J Med Chem; 2008 Jun; 51(11):3154-70. PubMed ID: 18479118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase.
    Elsinghorst PW; Tanarro CM; Gütschow M
    J Med Chem; 2006 Dec; 49(25):7540-4. PubMed ID: 17149883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor.
    Elsinghorst PW; Cieslik JS; Mohr K; Tränkle C; Gütschow M
    J Med Chem; 2007 Nov; 50(23):5685-95. PubMed ID: 17944454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of tacrine-thiadiazolidinone hybrids as dual acetylcholinesterase inhibitors.
    Dorronsoro I; Alonso D; Castro A; del Monte M; García-Palomero E; Martínez A
    Arch Pharm (Weinheim); 2005 Jan; 338(1):18-23. PubMed ID: 15674800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors.
    Hamulakova S; Janovec L; Hrabinova M; Spilovska K; Korabecny J; Kristian P; Kuca K; Imrich J
    J Med Chem; 2014 Aug; 57(16):7073-84. PubMed ID: 25089370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
    Muñoz-Ruiz P; Rubio L; García-Palomero E; Dorronsoro I; del Monte-Millán M; Valenzuela R; Usán P; de Austria C; Bartolini M; Andrisano V; Bidon-Chanal A; Orozco M; Luque FJ; Medina M; Martínez A
    J Med Chem; 2005 Nov; 48(23):7223-33. PubMed ID: 16279781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.
    Campiani G; Fattorusso C; Butini S; Gaeta A; Agnusdei M; Gemma S; Persico M; Catalanotti B; Savini L; Nacci V; Novellino E; Holloway HW; Greig NH; Belinskaya T; Fedorko JM; Saxena A
    J Med Chem; 2005 Mar; 48(6):1919-29. PubMed ID: 15771436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Design, synthesis and evaluation of tacrine-methoxybenzene hybrids as cholinesterases inhibitors].
    Luo W; Zhao YM; Zhang Z; Su YB; Wang CJ
    Yao Xue Xue Bao; 2012 Jul; 47(7):916-21. PubMed ID: 22993857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NO-donating tacrine derivatives as potential butyrylcholinesterase inhibitors with vasorelaxation activity.
    Chen Y; Sun J; Huang Z; Liao H; Peng S; Lehmann J; Zhang Y
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3162-5. PubMed ID: 23639542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as dual inhibitors for cholinesterases and amyloid beta aggregation.
    Luo W; Li YP; He Y; Huang SL; Tan JH; Ou TM; Li D; Gu LQ; Huang ZS
    Bioorg Med Chem; 2011 Jan; 19(2):763-70. PubMed ID: 21211982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties.
    Fernández-Bachiller MI; Pérez C; Monjas L; Rademann J; Rodríguez-Franco MI
    J Med Chem; 2012 Feb; 55(3):1303-17. PubMed ID: 22243648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of amino acid residues involved in the binding of Huperzine A to cholinesterases.
    Saxena A; Qian N; Kovach IM; Kozikowski AP; Pang YP; Vellom DC; Radić Z; Quinn D; Taylor P; Doctor BP
    Protein Sci; 1994 Oct; 3(10):1770-8. PubMed ID: 7849595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational design and synthesis of highly potent anti-acetylcholinesterase activity huperzine A derivatives.
    Yan J; Sun L; Wu G; Yi P; Yang F; Zhou L; Zhang X; Li Z; Yang X; Luo H; Qiu M
    Bioorg Med Chem; 2009 Oct; 17(19):6937-41. PubMed ID: 19726199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.
    Fang L; Appenroth D; Decker M; Kiehntopf M; Roegler C; Deufel T; Fleck C; Peng S; Zhang Y; Lehmann J
    J Med Chem; 2008 Feb; 51(4):713-6. PubMed ID: 18232655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.
    Pan L; Tan JH; Hou JQ; Huang SL; Gu LQ; Huang ZS
    Bioorg Med Chem Lett; 2008 Jul; 18(13):3790-3. PubMed ID: 18524585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors.
    Camps P; Formosa X; Muñoz-Torrero D; Petrignet J; Badia A; Clos MV
    J Med Chem; 2005 Mar; 48(6):1701-4. PubMed ID: 15771413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.